Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Zhengbin Yao
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 77
- Beta
- 1.35
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 26.51
Financials
Net Income
$-49.89MEBITDA
$-49.89MFree Cash Flow
$-39.58MEPS (diluted)
$-1.05Shares Outstanding (diluted)
47.61M+3630.2%Operating Expenses
$52.69MCash & Debt
$373.12MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-166.31M | $-4.32 |
| 2024 | $0.00 | $-80.49M | $-2.56 |
| 2023 | $0.00 | $-69.33M | $-2.17 |
| 2022 | $0.00 | $-36.91M | $-1.10 |
| 2021 | $0.00 | $-51.61M | $-40.44 |
Valuation
AVBPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
67-33.33%Social Signal Score
Mentions (3)
- Newsbusinesswire.com·6h ago·Negative
AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $AVBP--AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law.
View source ↗ - Newsbenzinga.com·1d ago·Negative
ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low ArriVent BioPharma Inc. (NASDAQ:AVBP) stock fell on Tuesday with a session volume of 14.10 million compared to the average volume of 524.163 thousand, according to Benzinga Pro data.
View source ↗ - Newsglobenewswire.com·56d ago·Neutral
ArriVent BioPharma Reports Second Quarter 2026 Financial Results NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent Company progress.
View source ↗
Earnings
Mon, Nov 16(in 6 weeks)
Consensus estimate $-1.07 per share
Typical surprise -6.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-1.05 vs $-0.99miss
- Mon, May 11$-0.96 vs $-0.88miss
- Thu, Mar 5$-0.78 vs $-0.87beat
- Mon, Nov 10$-0.83 vs $-0.78miss
- Mon, Aug 11$-0.90 vs $-0.70miss
- Mon, May 12$-1.90 vs $-0.66miss
Estimates and results for AVBP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AVBP officers and directors.
- Bought
- $26.0m
- Sold
- $13.0m
4 trades
1 trade
- Hillhouse Investment Management, Ltd.sold
- Hillhouse Investment Management, Ltd.bought
- Orbimed Advisors Llcbought
- Gordon Carl Lbought
- Healy Jamesbought
85 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AVBP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.